Treanda Recall Issued Due to Particulate Matter Contamination

One lot of the leukemia drug Treanda has been recalled after glass fragments were found in a vial.

The Treanda recall was announced on January 27 by the FDA, which indicated that the fragments could cause an embolism and could disrupt blood flow, leading to tissue/organ damage.

The FDA cautioned that patients undergoing surgery, individuals with suppressed or compromised immune systems, the elderly and patients with micro or macrovascular disease, like heart disease and kidney disease, were most vulnerable to injury from glass fragments injected with the drug, which is delivered intravenously.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

There have been no injuries or adverse events reported in connection to the Treanda particulate matter contamination.

The recall affects 8 mL vials of Treanda (bendamustine), manufactured by Cephalon, Inc. The vials have a lot number of TB30111 and an expiration date of 12/2012. They were distributed to wholesalers and retailers nationwide from March 22, 2011 through October 5, 2011.

Treanda (bendamustine HCl) is an intravenous injection approved by the FDA in 2008 for treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. It is manufactured by Cephalon and provides a reduced treatment time, as the infusion takes about an hour and can be done on an outpatient basis.

Side effects of Treanda have been linked to potentially fatal skin reactions known as Stevens-Johnson Syndrome and toxic epidermal necrolysis. At least one death has been reported after a user experienced the severe skin conditions from Treanda.

As a result of the particulate matter contamination, the FDA recommends that wholesalers, retailers and hospitals who have vials that belong to the affected lot in their possession immediately cease using them and quarantine the recalled Treanda for return. Known recipients of the recalled vials have been notified of the recall. Consumers with questions can call (877) 319-8965.

The FDA urges healthcare professionals and patients to report any adverse events or Treanda side effects to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted today)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.

Lawyers Propose Direct Filing of Toxic Baby Food Lawsuits Over Autism, ADHD in Federal MDL
Lawyers Propose Direct Filing of Toxic Baby Food Lawsuits Over Autism, ADHD in Federal MDL (Posted today)

A federal judge has been asked to allow direct filing of future baby food lawsuits over autism and ADHD side effects with the MDL court, but the parties disagree over whether that order should allow multi-plaintiff complaints.

Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General
Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General (Posted 2 days ago)

U.S. Surgeon General says social media platforms like Facebook, Instagram and Tiktok should carry label warnings, alerting parents that youth who use the platforms face an increased risk of mental health side effects.